Trial Profile
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Rabeprazole (Primary)
- Indications Reflux oesophagitis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 13 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Dec 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2015 according to ClinicalTrials.gov record.
- 16 Dec 2014 Planned primary completion date changed from 1 Mar 2013 to 1 Mar 2015 according to ClinicalTrials.gov record.